Back to News
Dec 11, 2025 12:40 PM

Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease

On Wednesday, Roche Holdings AG (OTC:RHHBY) shared data from the phase 3 lidERA Breast Cancer study.

The study evaluated giredestrant as an adjuvant endocrine treatment for oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, early-stage breast cancer.

The lidERA results were presented at the 2025 San Antonio Breast Cancer Symposium.

Roche, in a press release on Wednesday, said Giredestrant is the first and only oral selective oestrogen receptor degrader (SERD) to show superior iDFS in the adjuvant setting, and lidERA is the second positive phase 3 readout for giredestrant following the evERA Breast Cancer results ...